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Abstract
Background: Asymptomatic carriage of COVID-19 in pregnant women has been reported and could lead to
outbreaks in maternity units. We sought to ascertain the impact of rapid isothernal nucleic acid based testing for
COVID-19 in an unselected cohort of pregnant women attending our maternity unit. We also assessed the
correlation between community prevalence and asymptomatic carriage.
Methods: Data for the retrospective cohort study were collected from a large UK tertiary maternity unit over a 4-
week period using computerised hospital records. Literature searches were performed across multiple repositories.
COVID-19 prevalence was extracted from online repositories.
Results: Nasopharyngeal and oropharyngeal swabs were obtained from 457/465 (98%) women during the study
period. The median turnaround time for results was 5.3 h (interquartile range (IQR) 2.6–8.9 h), with 92% of the
results returned within 24 h. In our cohort, only one woman tested positive, giving a screen positive rate of 0.22%
(1/457; 95% CI: 0.04–1.23%). One woman who tested negative developed a fever postnatally following discharge
but was lost to follow-up. From our literature review, we did not find any correlation between asymptomatic
carriage in pregnant women and the reported regional prevalence of COVID-19.
Conclusions: Testing using the SAMBA-II machine was acceptable to the vast majority of pregnant women
requiring admission and had a low turnaround time. Asymptomatic carriage is low, but not correlated to
community prevalence rates. Screening pregnant women on admission will remain an important component in
order to minimise nosocomial infection.
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Background
The World Health Organization (WHO) characterized
Coronavirus disease 2019 (COVID-19) as a global pan-
demic caused by severe acute respiratory syndrome cor-
onavirus 2 (SARS-CoV-2) in March 2020 [1]. The first
case series was described by Huang et al. [2] where 41
patients were admitted to Jin Yin-Tan Hospital in Wu-
han, China. Of the 41 confirmed cases, 98% had fever
and 76% had a dry cough, all developed pneumonia.
Deep sequencing of lower respiratory tract samples iden-
tified the viral genome to be from the coronavirus family
and this was named (COVID-19). Cellular access is
gained through a spike protein that binds to the
angiotensin-converting enzyme 2 receptor (ACE2), and
viral uptake is promoted by the type 2 transmembrane
serine protease (TMPRSS2) [3]. Lauer reported a median
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5.7 days to fever onset (CI 4.9–6.8 days), and 97.5% of
cases had a fever within 12.5 days (CI 8.2–17.7 days of
exposure) [4]. Importantly, COVID-19 often takes a pro-
longed disease course with viral load in throat and nose
declining after the first week as antibody titres rise [5].
This can result in nucleic acid testing becoming negative
after the first week, though neutralisation and SARS-
CoV-2 antibodies are readily detectable in nearly all
cases [6]. Asymptomatic carriage of COVID-19 was esti-
mated to be 15% in general population [7] and Sutton
et al. [8] reported that positive rate of 13.7% (29/210)
among asymptomatic group and 87.9% (29/33) of preg-
nant women infected with SARS-CoV-2 were asymp-
tomatic at presentation.
Identification of asymptomatic pregnant women with
COVID-19 is important for several reasons. Firstly, iden-
tification of asymptomatic carriers would allow changes
in the pathway of care so as to prevent nosocomial in-
fections, reducing the risk of asymptomatic transmission
to other pregnant women and also to healthcare workers
(HCW). Testing also enables early isolation and rational-
isation of personal protective equipment (PPE). Thirdly,
identification of viral carriage could allow closer moni-
toring both during and after delivery, consideration of
low molecular heparin for prophylaxis of venous
thromboembolism, and longer term follow-up.
SAMBA II is an isothermal point of care nucleic acid
amplification based platform with a detection limit of
around 250 genome copies/ml [9]. It has previously been
clinically validated in parallel with standard reverse tran-
scription polymerase chain reaction (RT-PCR) with sen-
sitivity and specificity of 96.9% (95% CI 84.2–99.9) and
100% (95% CI 96.9–100) for COVID-19, respectively.
The median time to result has been significantly reduced
from 26.4 h (IQR 21.4 to 31.4) for the standard lab RT-
PCR test to 2.6 h (IQR 2.3 to 4.8) for SAMBA II SARS-
CoV-2 test [10].
The aims of this paper are two-fold: to ascertain the
incidence of asymptomatic carriage in our maternity unit
using a rapid diagnostic testing platform; and to assess if
the rate of carriage of COVID-19 in asymptomatic preg-
nant women correlated with peak local prevalence.
Methods
Study design and setting
Cambridge University Hospitals NHS Foundation Trust
(CUH) covers a large geographical area with a total popu-
lation of approximately 5 million people in the east of
England. The Rosie Maternity Hospital is part of CUH,
with an annual delivery rate of approximately 5500
women. All admissions to the Rosie Maternity Hospital
were offered a nasopharyngeal (NP) and oropharyngeal
(OP) swab for COVID-19. These included women who
were required antenatal and postnatal admission to the
obstetric wards, women attending the main delivery unit
and birth centre, and women attending for elective Cae-
sarean Section or cerclage insertion. All staff members re-
ceived training prior to obtaining swabs. Samples were
processed using the SAMBA II machine (Diagnostics for
the Real World, Chesterford, UK) [11, 12]. Data were ex-
tracted for population demographics and symptomatol-
ogy. Symptoms were defined as fever and or cough in line
with Public Health England’s advice at the time. Patients
who were asymptomatic were defined as women who
lacked a fever and/or cough from the time of testing to
discharge. Turnaround time was defined as the time the
swab was collected, to the time a result was uploaded onto
the electronic hospital record. Where time entries were
missing, electronic hospital notes were retrieved to check
for a record of sample collection and availability of results.
These were computed separately. Our study was regis-
tered as a service evaluation project and ethical approval
was not required.
Data and literature review
We conducted a literature search from PubMed,
Cochrane COVID-19 trials for published studies, MedR-
xiv for pre-prints and an unofficial online repository on
15/05/2020 and updated on 07/08/2020. Where datasets
from the same institution were replicated in more than
one publication, but with a larger sample size or longer
duration, the publication with the largest sample size
and/or duration was selected. Data were extracted for
case definition, diagnostic test employed, duration of fol-
low up, gestational age at the time of testing and turn-
around time. In order to assess if the prevalence of
COVID-19 positive symptomatic and asymptomatic
pregnant women correlated with local prevalence rates,
we extracted local population COVID-19 prevalence
rates for each of the included studies from open source
repositories (Supplementary information).
Statistical analysis
Data were analysed using GraphPad Prism version 5.00
for Windows, GraphPad Software, San Diego California
USA, www.graphpad.com. Data were extracted by two
reviewers (RX and HC), and disagreements were re-
solved by discussion with a 3rd reviewer (TP).
Results
SAMBA-II results
During the period 07/05–06/06 (4 weeks) 465 women
attended the Rosie Maternity Hospital for obstetric indi-
cations. NP and OP swabs were obtained from 457/465
women upon admission (98%). 18 (3.84%) women had
more than one swab taken either due to prolonged in-
patient admission beyond 7 days, or reattendance within
the 4 week period. Self-reported ethnicity was available
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for 99.5% of women. The majority of our population
consisted of White British, Irish or European ancestery
(407/465, 87.5%) and this is reflective of the local popu-
lation in Cambridgeshire. The median gestational age at
the time of the admission swab was 39 weeks (Interquar-
tile range (IQR) 37–40 weeks). Six women (1.3%)
attended in the postnatal period due to obstetric con-
cerns. The median duration of inpatient stay for all pa-
tients was two days (IQR 1–3). The median duration of
follow-up in the post-natal period was 5 days (IQR 3–9).
None of the women had a cough on admission. 37/465
women developed a fever either during labour or follow-
ing delivery (7.9%). All 37 women had a negative result
on admission, and the fever was attributed to an obstet-
ric cause. Two women were admitted with breathless-
ness on a background of cardiac disease. One woman
developed symptoms of fever or sore throat four days
after delivery. Advice from Public Health England at the
time was to contact a national helpline and she was lost
to follow up.
Only one woman in our cohort tested positive over
this four-week interval. This woman had neither cough
nor fever on admission, but had symptoms of altered
taste and smell four weeks prior to her admission. To
ensure that this was a true positive, NP and OP swabs
were repeated using the SAMBA II machine (but not in-
cluded in our current analyses for TAT) until she tested
negative. As this patient remained symptom-free during
admission, she would be the only true asymptomatic
COVID-19, giving an asymptomatic carriage rate of
0.22% (1/457; 95% CI: 0.04–1.23%). Knowledge of her
results enabled HCW to convert from using standard
surgical masks, plastic aprons and gloves to full personal
protective equipment when caring for this patient.
Result turnaround times (TAT) were verified and
available for 432/457 (94.5%) samples. The median TAT
was 5.3 h (IQR 2.6–8.9) (Fig. 1), with 93.9% (429/457) of
sample results returned within 24 h. Where sample turn-
around times were absent, these were due to an under-
estimation of turnaround times rather than a delay in
sample processing. This information was gleaned from
verbatim entries in the patient records regarding the
sample obtained, and the results entered. As no specific
record of time was entered, these were excluded from
further analyses. A small percentage (16/465, 3.4%) of
women declined to be swabbed on admission, 5 of them
were in discomfort from labour therefore declined test-
ing. No reasons were given for the remaining 11 women
who declined testing.
Literature review
Four hundred and seven articles were screened for title
and abstract and 46 full-text articles assessed for inclu-
sion. 17 universal screening studies [13–29] (Table 1)
were selected to assess if the prevalence of COVID-19
positive pregnant women correlated with local preva-
lence rates as these papers fulfilled our prespecified cri-
teria above.
We found a correlation between the test positivity with
the regional background prevalence rates of COVID-19.
There was a direct correlation between the number of
confirmed cases at the peak (R2 = 0.41, p = 0.0053) (Fig. 2b)
Fig. 1 Results turnaround times (TAT) from 432 SARS-CoV-2 testing samples, using SAMBA II for in-hospital testing
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and end of the study period with those who tested
positive (R2 = 0.48, p = 0.002) (Fig. 2c), but not with
the number of confirmed cases at the start of the
study period (R2 = 0.004, p = 0.82) (Fig. 2a). There
was no correlation between the proportions of asymp-
tomatic pregnant carriers with background infection
rates (Fig. 3).
Only three papers reported turnaround time. Breslin
et al. [33] reported an average of 8 h for 43 women
screened [Conventional PCR, (New York, New York)]
and LaCourse et al. [17] reported a median turnaround
time of 2.5 h for rapid testing [DiaSorin Simplexa (MDX
Liaison) EUA assay, n = 82 women] and 7.1 h for routine
PCR (Seattle, Washington). London et al. [29] reported
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an average turnaround time of 5 h using GeneXpert PCR
in a cohort of 75 women (Brooklyn, New York).
Discussion
Main findings
Our work summarises existing literature on universal
screening of asymptomatic carriage of COVID-19 in preg-
nant women with specific reference to the turnaround
time of results, and local prevalence rates. The key findings
of our study are threefold. We captured data on all atten-
dances in a large UK maternity hospital and ours is the lar-
gest, to have reported turnaround times of less than 24 h
in over 90% of samples returned. We were also able to
demonstrate a high acceptability of COVID-19 screening
amongst our maternity population with only 3% declining
to be tested. Thirdly, ours is the first study to demonstrate
the utility of point of care testing in an unselected cohort
of pregnant women attending a large UK maternity unit.
Whilst the data are reflective of our maternity service,
laboratory services were also processing samples from pa-
tients attending the accident and emergency department,
and medical and surgical wards within a national health
service. We were still able to achieve a short turnaround
time of five hours. This allowed for changes to be made
within postnatal care pathway, and escalation of the use of
personal protective equipment. Testing of newborns could
have also been performed had it been required.
The low positive screening rate in our cohort may be
partly explained by the low rates of infection in the east of
England (cumulative infection rate 0.42%), in comparison
to 1.27% in California and 2.12% in New York. As the
pandemic evolved, advice and guidance were issued to
pregnant women in the UK, who may have adopted behav-
ioural changes that minimised interaction with the general
public. Additionally, home working and minimising the
commute to work could have protected them further.
Interestingly, the proportion of asymptomatic carriers did
not correlate with the regional infection rate. Possible ex-
planations include variations in mask wearing, local test
and trace strategies, movement control orders and specific
advice on “shielding” in pregnant women [34].
Many hospitals introduced visiting restrictions during
the lockdown, and ours was no different. Partners were
Fig. 2 Relationship between prevalence of COVID-19 in pregnant
women and published peak prevalence. Data from Table 1 was used
to generate Figure 2. Simple linear regression was performed to
investigate the relationship between the prevalence of COVID-19 in
pregnant women and peak daily community prevalence at three time
points: the start of the study interval the maximum reported daily
prevalence and the prevalence at the end of the study interval. The
scatter plots demonstrated a positive correlation with the maximum
reported daily prevalence rates during the study interval (R2 = 0.41,
p = 0.0053) and towards the end of the study period (R2 = 0.48, p =
0.002) but not with rates at the start (R2 = 0.004, p = 0.82)
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not allowed to attend the antenatal ward nor ultrasound
scan appointments. Obstetric and non-obstetric face-to-
face clinic appointments were changed to phone ap-
pointments where possible, thus reducing footfall within
the hospital premises. Staff working in clinical areas
were required to wear personal protective equipment in
the form of a surgical mask, gloves and aprons as a mini-
mum, and FFP3 masks for aerosol generating proce-
dures. Thus, pregnant women attending hospital should
also be reassured, not only that asymptomatic carriage
of COVID-19 is low, infection within the inpatient set-
ting is low. Whether or not this is maintained against a
backdrop of rising COVID-19 infections rates is
unknown.
Strengths and limitations
We did not compare the test accuracy of the Samba-II
machine in our population. However, this device has
been tested previously in a cohort of over 1000 individ-
uals and found to have 97% accuracy to conventional
RT-PCR testing [10]. There is no reason to believe why
it should perform differently in pregnant women. In
contrast, GeneXpert PCR testing has been previously
been validated on a much smaller cohort of less than 50
women [35]. We did not perform radiological investiga-
tions to look for manifestations of COVID-19 pneumo-
nia, as some others have clinical diagnosis criteria as
well as laboratory diagnosis [36, 37]. Women could
therefore have a negative NP or OP result for COVID-
19, but have radiological changes. However, the likeli-
hood of this is low. Although we had a high acceptability
rate, we did not explore women’s and staff views on
screening for COVID-19, thus further research is re-
quired to evaluate this. For example, there may be a
need to develop tests which are acceptable to women in
labour, or training for hospital staff in contact tracing
where women simply declined to be tested. In the inter-
est of patient safety, we would suggest a conservative ap-
proach to patient pathways for women who decline
testing so as not to result in contagion within the hos-
pital setting.
We accept that anosmia and lack of taste can be con-
sidered a symptom of COVID-19 infection. However, we
used pre-specified criteria for asymptomatic screening to
ensure consistency in case definition so as not to exclude
women screened prior to 18/5/2020, when changes in
symptom definition were published [38]. Indeed, Allotey
et al. have subsequently demonstrated that only 5% of
asymptomatic pregnant and recently pregnant women
with COVID-19 exhibit altered sense of taste [34]. Given
that only one woman tested positive in our cohort, in-
clusion of anosmia and or ageuisia as a symptom would
not alter our results as her symptoms had resolved by
the time she was tested. As the Samba-II process is not
based on cycle time we are unable to comment on viral
load for this patient. However Celik et al. have demon-
strated that Covid-19 viral shedding from the upper re-
spiratory tract has a mean duration of 17 days (up to a
Fig. 3 Relationship between asymptomatic carriage of COVID-19 in
pregnant women and local peak prevalence. Data from Table 1 was
used to generate Figure 3. Simple linear regression was performed
to investigate the relationship between the prevalence of COVID-19
in pregnant women and peak daily community prevalence at three
time points: the start of the study interval, during and end of the
study interval. The scatter plots demonstrated no correlation with
the maximum reported daily prevalence rates at the start (R2 = 0.04,
p = 0.44), during (R2 = 0.01, p = 0.65) and end of the study intervals
(R2 = 0.02, p = 0.62)
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maximum of 83 days) but is not infectious beyond day 9
of illness [39].
A potential limitation of SAMBA II testing relates to
financial implications as the machine costs £35,000 with
test capsules costing £35 each. The financial cost impli-
cations of asymptomatic screening within maternity has
not been evaluated. However, given the high infectivity
of COVID-19, asymptomatic screening within a hospital
setting will remain an important component so as to
avoid nosocomial infection, prevent patient-to-staff in-
fection, and to rationalise the use of full personal pro-
tective equipment. Another disadvantage is testing
capacity, given that each machine can only handle only
one test at a time, and each run lasting 1.5 h. Our unit
has mitigated this by running 20 machines simultan-
eously. Additional barriers have been manufacturing
enough machines, reagents and cartridges for testing.
Nonetheless SAMBA II has been procured by NHS Eng-
land and is being implemented in over 100 sites
nationally.
Conclusion
The Royal College for Obstetricians and Gynaecologists
in the UK have recently published guidelines on testing
for asymptomatic pregnant women attending maternity
units [40]. These are broadly in line with our current
practice but for the type of swab being offered (conven-
tional lab based RT-PCR as opposed to rapid testing
with the SAMBA II). Owing to the variable rates of
asymptomatic carriage of COVID-19 in pregnant
women, and the rapid turnaround time using the
SAMBA II machine, we propose the introduction of
SAMBA II or other point of care testing platforms in
maternity units as an accurate and acceptable test to
pregnant women requiring admission.
Supplementary Information




NP: Nasopharyngeal; OP: Oropharyngeal; CUH: Cambridge University
Hospitals NHS Foundation Trust; COVID-19: Coronavirus-19; TAT: Results
turnaround time; RT-PCR: Real time quantitative fluorescence polymerase
chain reaction; IQR: Interquartile range
Acknowledgements
We are grateful to all the pregnant women for their co-operation with
COVID-19 screening during the pandemic.
Authors’ contributions
HC conceived the study. HML, RG, RH and HC designed the study. RX and
HC screened titles and abstracts for inclusion and literature review. HC, RX
and TP extracted and analysed data. HML helped interpret the study findings
from a clinical viewpoint. HC and RX wrote the first draft, which all authors
revised for critical content. All authors approved the final manuscript. HC is
the guarantor. The guarantor had full access to all the data in the study, take
responsibility for the integrity of the data and the accuracy of the data
analysis, and had final responsibility for the decision to submit for
publication. The corresponding author attests that all listed authors meet




Availability of data and materials
The datasets generated for the cohort study are not publically available due
to current UK regulations with regards to data protection, but are available
from the corresponding author on reasonable request. The datasets
generated for the peak coronavirus prevalence rates can be found from
international repositories listed in the references.
Ethics approval and consent to participate
This work was registered as service evaluation project (ID 3079). All women
booked for maternity care at the Rosie Maternity Hospital are asked verbally
whether they give their consent for data to be used for research and this is
recorded in their computerised hospital records. We can therefore confirm
that this is a formally approved method of consenting for use of data in
research at the Rosie Maternity Unit. Identifiable data were removed from
cases to ensure anonymity. Identifiable data were removed from cases to
ensure anonymity. Additionally, in accordance with the United Kingdom
National Health Service National Research Ethics Service guidance, neither
individual informed consent nor formal research ethics committee review
was required, because the study was undertaken by the direct clinical team




All authors have completed the ICMJE uniform disclosure form at www.
icmje.org/coi_disclosure.pdf and declare: no support from any organisation
for the submitted work; no financial relationships with any organisations that
might have an interest in the submitted work in the previous three years, no
other relationships or activities that could appear to have influenced the
submitted work. Completed disclosure of interest forms are available to view
online as supporting information.
Author details
1Department of Obstetrics & Gynaecology, Rosie Maternity Hospital,
Cambridge CB2 0SQ, UK. 2Department of Anaesthesia, Cambridge University
NHS Hospitals Foundation Trust, Cambridge CB2 0QQ, UK. 3Department of
Medicine, University of Cambridge, Cambridge CB2 0AW, UK.
Received: 28 October 2020 Accepted: 18 February 2021
References
1. WHO. Rolling updates on coronavirus disease (COVID-19). https://www.who.
int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.
Accessed 1 Aug 2020.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
patients infected with 2019 novel coronavirus in Wuhan, China. Lancet
(London, England). 2020;395:497–506. https://doi.org/10.1016/S0140-6736(2
0)30183-5.
3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S,
et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked
by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271–80.e8. https://
doi.org/10.1016/j.cell.2020.02.052.
4. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The
incubation period of coronavirus disease 2019 (COVID-19) from publicly
reported confirmed cases: estimation and application. Ann Intern Med.
2020;172:577–82. https://doi.org/10.7326/M20-0504.
5. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to
SARS-CoV-2 in Patients with Novel Coronavirus Disease 2019. Clin Infect Dis.
2020;71:2027–34. https://doi.org/10.1093/cid/ciaa344.
Xu et al. BMC Pregnancy and Childbirth          (2021) 21:212 Page 7 of 8
6. Mlcochova P, Collier D, Ritchie A, Assennato SM, Hosmillo M, Goel N, et al.
Combined point-of-care nucleic acid and antibody testing for SARS-CoV-2
following emergence of D614G spike variant. Cell Reports Medicine. 2020;1.
7. Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Salanti
G, et al. The role of asymptomatic SARS-CoV-2 infections: rapid living
systematic review and meta-analysis. 2020.
8. Sutton D, Fuchs K, D’Alton M, Goffman D. Universal Screening for SARS-CoV-
2 in Women Admitted for Delivery. New England J Med. 2020;382:2163–4.
https://doi.org/10.1056/nejmc2009316.
9. Assennato SM, Ritchie AV, Nadala C, Goel N, Zhang H, Datir R, et al.
Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for
detection of SARS-CoV-2. medRxiv. 2020. https://doi.org/10.1101/2020.
05.24.20100990v3.
10. Collier DA, Assennato SM, Warne B, Sithole N, Sharrocks K, Ritchie A, et al.
Point of care nucleic acid testing for SARS-CoV-2 in hospitalized patients: a
clinical validation trial and implementation study. Cell Reports Medicine.
2020;1. https://doi.org/10.1016/j.xcrm.2020.100062.
11. Rivett L, Routledge M, Sparkes D, Warne B, Bartholdson J, Cormie C, et al. Screening
of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage
in COVID-19 transmission. eLife. 2020; epub ahead of print.
12. Sridhar S, Forrest S, Kean I, Young J, Scott JB, Maes M, et al. A blueprint for
the implementation of a validated approach for the detection of SARS-Cov2
in clinical samples in academic facilities. bioRxiv. 2020;:2020.04.14.041319.
https://doi.org/10.1101/2020.04.14.041319.
13. Fassett MJ, Lurvey LD, Yasumura L, Nguyen M, Colli JJ, Volodarskiy M, et al.
Universal SARS-Cov-2 screening in women admitted for delivery in a large
managed care organization. Am J Perinatol. 2020. https://doi.org/10.1055/s-
0040-1714060.
14. Gagliardi L, Danieli R, Suriano G, Vaccaro A, Tripodi G, Rusconi F, et al.
Universal severe acute respiratory syndrome coronavirus 2 testing of
pregnant women admitted for delivery in 2 Italian regions. Am J Obstet
Gynecol. 2020;223:291–2. https://doi.org/10.1016/j.ajog.2020.05.017.
15. Herraiz I, Folgueira D, Villalaín C, Forcén L, Delgado R, Galindo A. Universal
screening for SARS-CoV-2 before labor admission during Covid-19 pandemic
in Madrid. J Perinat Med. 2020. https://doi.org/10.1515/jpm-2020-0236.
16. Naqvi M, Burwick RM, Ozimek JA, Greene NH, Kilpatrick SJ, Wong MS. Severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal testing
experience on a Los Angeles labor and delivery unit. Obstet Gynecol. 2020;
136:235–6. https://doi.org/10.1097/AOG.0000000000003987.
17. LaCourse SM, Kachikis A, Blain M, Simmons LE, Mays JA, Pattison AD, et al.
Low prevalence of SARS-CoV-2 among pregnant and postpartum patients
with universal screening in Seattle, Washington. Clinical Infect Dis. 2020.
https://doi.org/10.1093/cid/ciaa675.
18. Ceulemans D, Thijs I, Schreurs A, Vercammen J, Lannoo L, Deprest J, et al.
Screening for COVID-19 at childbirth: is it effective? Ultrasound Obstetrics
Gynecol. 2020;56:113–4. https://doi.org/10.1002/uog.22099.
19. Miller ES, Grobman WA, Sakowicz A, Rosati J, Peaceman AM. Clinical
implications of universal severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) testing in pregnancy. Obstet Gynecol. 2020;136:232–4. https://
doi.org/10.1097/AOG.0000000000003983.
20. Ochiai D, Kasuga Y, Iida M, Ikenoue S, Tanaka M. Universal screening for
SARS-CoV-2 in asymptomatic obstetric patients in Tokyo, Japan. In J
Gynaecol Obstetrics. 2020;150:268–9. https://doi.org/10.1002/ijgo.13252.
21. Campbell KH, Tornatore JM, Lawrence KE, Illuzzi JL, Sussman LS, Lipkind HS,
et al. Prevalence of SARS-CoV-2 among patients admitted for childbirth in
southern Connecticut. JAMA. 2020;323. https://doi.org/10.1001/jama.2020.8904.
22. Khalil A, Hill R, Ladhani S, Pattisson K, O’Brien P. Severe acute respiratory
syndrome coronavirus 2 in pregnancy: symptomatic pregnant women are
only the tip of the iceberg. Am J Obstet Gynecol. 2020. https://doi.org/10.1
016/j.ajog.2020.05.005.
23. Yassa M, Yirmibes C, Cavusoglu G, Eksi H, Dogu C, Usta C, et al. Outcomes
of universal SARS-CoV-2 testing program in pregnant women admitted to
hospital and the adjuvant role of lung ultrasound in screening: a
prospective cohort study. J Maternal-Fetal Neonatal Med. 2020:1–7. https://
doi.org/10.1080/14767058.2020.1798398.
24. Prabhu M, Cagino K, Matthews KC, Friedlander RL, Glynn SM, Kubiak JM,
et al. Pregnancy and postpartum outcomes in a universally tested
population for SARS-CoV-2 in New York City: a prospective cohort study.
BJOG. 2020. https://doi.org/10.1111/1471-0528.16403.
25. Dória M, Peixinho C, Laranjo M, Mesquita Varejão A, Silva PT. Covid-19
during pregnancy: a case series from an universally tested population from
the north of Portugal. Eur J Obstet Gynecol Reprod Biol. 2020;250:261–2.
https://doi.org/10.1016/j.ejogrb.2020.05.029.
26. Sutton D, Fuchs K, D’Alton M, Goffman D. Universal screening for SARS-CoV-
2 in women admitted for delivery. N Engl J Med. 2020;382:2163–4. https://
doi.org/10.1056/NEJMc2009316.
27. Buckley A, Bianco A, Stone J. Universal testing of patients and their support
persons for severe acute respiratory syndrome coronavirus 2 when
presenting for admission to labor and delivery at Mount Sinai Health
System. Am J Obstet Gynecol MFM. 2020:100147. https://doi.org/10.1016/J.A
JOGMF.2020.100147.
28. Vintzileos WS, Muscat J, Hoffmann E, John NS, Vertichio R, Vintzileos AM,
et al. Screening all pregnant women admitted to labor and delivery for the
virus responsible for coronavirus disease 2019. Am J Obstet Gynecol. 2020;
223:284–6. https://doi.org/10.1016/j.ajog.2020.04.024.
29. London V, McLaren R, Atallah F, Cepeda C, McCalla S, Fisher N, et al. The
relationship between status at presentation and outcomes among pregnant
women with COVID-19. Am J Perinatol. 2020;37:991–4. https://doi.org/10.1
055/s-0040-1712164.
30. Johns Hopkins University of Medicine Coronavirus Resource Center. https://
coronavirus.jhu.edu/data.
31. GOV.UK. Coronavirus (COVID-19) in the UK. https://coronavirus.data.gov.uk/cases.
32. WHO Coronavirus Disease (COVID-19) Dashboard. 2020. https://covid19.who.int/.
33. Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K,
et al. Coronavirus disease 2019 infection among asymptomatic and
symptomatic pregnant women: two weeks of confirmed presentations to
an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM.
2020:100118. https://doi.org/10.1016/j.ajogmf.2020.100118.
34. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical
manifestations, risk factors, and maternal and perinatal outcomes of
coronavirus disease 2019 in pregnancy: living systematic review and meta-
analysis. The BMJ. 2020;370:3320. https://doi.org/10.1136/bmj.m3320.
35. Goldenberger D, Leuzinger K, Sogaard KK, Gosert R, Rolo T, Naegele K, et al.
Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay. J Virol
Methods. 2020; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351036/.
36. Commision CNH. Chinese Clinical Guidance for COVID-19 Pneumonia
Diagnosis and Treatment (7th edition) 抗击新冠肺炎. http://kjfy.
meetingchina.org/msite/news/show/cn/3337.html. Accessed 24 Jun 2020.
37. Liao J, He X, Gong Q, Yang L, Zhou C, Li J. Analysis of vaginal delivery
outcomes among pregnant women in Wuhan, China during the COVID-19
pandemic. Int J Gynecol Obstet. 2020;150:53–7. https://doi.org/10.1002/
ijgo.13188.
38. GOV.UK. Statement from the UK Chief Medical Officers on an update to
coronavirus symptoms. 2020. https://www.gov.uk/government/news/sta
tement-from-the-uk-chief-medical-officers-on-an-update-to-coronavirus-
symptoms-18-may-2020. Accessed 20 Dec 2020.
39. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-
CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and
infectiousness: a systematic review and meta-analysis. The Lancet Microbe.
2020;5247:1–10. https://doi.org/10.1016/s2666-5247(20)30172-5.
40. RCOG. Principles for the testing and triage of women seeking maternity
care in hospital settings, during the COVID-19 pandemic. 2020. https://
www.rcog.org.uk/globalassets/documents/guidelines/2020-08-10-principles-
for-the-testing-and-triage-of-women-seeking-maternity-care-in-hospital-
settings-during-the-covid-19-pandemic.pdf. Accessed 15 Aug 2020.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Xu et al. BMC Pregnancy and Childbirth          (2021) 21:212 Page 8 of 8
